Acropolis Investment Management LLC Has $1.62 Million Position in AbbVie Inc. $ABBV

Acropolis Investment Management LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 115.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company’s stock after purchasing an additional 3,746 shares during the quarter. Acropolis Investment Management LLC’s holdings in AbbVie were worth $1,616,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Hobart Private Capital LLC raised its holdings in shares of AbbVie by 4.4% in the 3rd quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock worth $261,000 after acquiring an additional 48 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in AbbVie by 1.1% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock valued at $848,000 after purchasing an additional 51 shares during the last quarter. FF Advisors LLC increased its holdings in AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after purchasing an additional 53 shares in the last quarter. Landaas & Co. WI ADV raised its stake in shares of AbbVie by 1.1% in the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after purchasing an additional 53 shares during the last quarter. Finally, Bernardo Wealth Planning LLC lifted its holdings in shares of AbbVie by 2.9% in the second quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock valued at $354,000 after purchasing an additional 53 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ABBV has been the subject of several recent research reports. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. UBS Group lifted their price objective on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. JPMorgan Chase & Co. increased their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Price Performance

ABBV opened at $224.32 on Thursday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a 50-day moving average of $226.87 and a 200 day moving average of $210.61. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The firm has a market cap of $396.47 billion, a P/E ratio of 169.94, a PEG ratio of 1.27 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the previous year, the company earned $3.00 earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.